Search Results - "Mallikaarjun, S."

Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole by Boulton, D. W., Kollia, G. D., Mallikaarjun, S., Kornhauser, D. M.

“…Summary What is known and Objective:  The antipsychotic, aripiprazole, plus lithium or valproate demonstrates rapid and significant improvement in manic…”
Get full text

The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder by Boulton, DW, Balch, AH, Royzman, K., Patel, CG, Berman, RM, Mallikaarjun, S., Reeves, RA

“…Possible effects of the atypical antipsychotic aripiprazole on the pharmacokinetics of standard antidepressant therapies (ADTs) were assessed in two…”
Get full text

2283 – Safety and tolerability of aripiprazole once-monthly initiated in adults with schizophrenia stabilized on atypical oral antipsychotics other than aripiprazole by Potkin, S, Raoufinia, A, Mallikaarjun, S, Bricmont, P, Peters-Strickland, T, Kasper, W, Jin, N, Baker, R.A, Eramo, A, Sanchez, R, McQuade, R.D

“…Objective Evaluate the safety and tolerability of aripiprazole once-monthly (ARI-OM) initiation in patients stabilized on oral antipsychotics other than…”
Get full text

Two days of fluvoxamine dosing significantly inhibits CYP1A2 by Bergman, K., Shoaf, S. E., Mallikaarjun, S.

“…Fluvoxamine (FLV) is frequently used in drug‐drug interaction studies as an inhibitor of CYP1A2. FLV administration is known to produce adverse events that may…”
Get full text

Aripiprazole in child and adolescent psychiatric disorders: Safety, tolerability, and pharmacokinetics by Nyilas, M, Auby, P, Mallikaarjun, S, Forbes, A, Carson, W.H

Get full text

Aripiprazole in child and adolescent psychiatric disorders: Effectiveness preliminary report by Auby, P, Nyilas, M, Mallikaarjun, S, Forbes, A, Carson, W.H

Get full text

Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers by Mallikaarjun, Suresh, Salazar, Daniel E., Bramer, Steven L.

“…Two 14‐day, placebo‐controlled, double‐blind studies evaluated the fasting pharmacokinetics, safety, and tolerability of aripiprazole, a new antipsychotic, in…”
Get full text

Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole: Pharmacokinetics of lithium/valproate with aripiprazole by Boulton, D. W., Kollia, G. D., Mallikaarjun, S., Kornhauser, D. M.

Get full text

Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate by Citrome, Leslie, Josiassen, Richard, Bark, Nigel, Salazar, Daniel E., Mallikaarjun, Suresh

“…The objective of this study was to assess the pharmacokinetics of the antipsychotic aripiprazole when coadministered with lithium or valproate. Two open‐label,…”
Get full text

PI-38 by Mallikaarjun, S., Bramer, S. L., Kornhauser, D., Saha, A.

“…BACKGROUND/AIMS This study investigated the tolerability, safety and pharmacokinetics of aripiprazole at doses up to 90 mg/day. METHODS This randomized,…”
Get full text

PI-38Tolerability, safety and pharmacokinetics of aripiprazole at high doses in adults with a diagnosis of schizophrenia or schizoaffective disorder - a pilot study by MALLIKAARJUN, S, BRAMER, S, KORNHAUSER, D, SAHA, A

Get full text

Acid-base / Electrolytes by An, J. N., Lee, J. P., Oh, Y. K., Lim, C. S., Shoaf, S., Bricmont, P., Mallikaarjun, S., Volpini, R. A., De Braganca, A. C., Canale, D., Goncalves, J. G., Brandao, T. P. B., Andrade, L., Seguro, A. C., Shimizu, M. H. M., Lee, J., Joo, K. W., Jung, Y. C., Earm, J.-H., Han, J. S., Poch, E., Burst, V., Greenberg, A., Makin, A., Chase, S., Walther, B., Blom, R. E., Van Dijken, G. D., Hene, R. J., Yu-Bao, W., Valerie, L., Thomas, E., Arvid, M., Alain, D., Pierre-Yves, M., Feraille, E., Tovbin, D., Avnon, L., Bloch, D., Zlotnik, M., Abdelkadir, A., Storch, S., Fezeu, L., Bankir, L., Hansel, B., Guerrot, D., Anzai, N., Jutabha, P., Tolle, M., Jankowski, V., Kretschmer, A., Santos, R. A. S., Zidek, W., Jankowski, J., Bader, M., Bourderioux, M., Ida Chiara, G., Thao, N.-K., Ludovic, J., Cerina, C., Gabrielle, P., Bertrand, K., Estelle, E., Bernard, E., Aleksander, E., Picard, N., Loffing, J.

Get full text

PIII-10Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in healthy subjects by VANWART, S, CIRINCIONE, B, LUDWIG, E, CHEN, X, SHOAF, S, GRASELA, T, MALLIKAARJUN, S

Get full text

OI-A-1Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in patients with congestive heart failure (CHF) and/or hyponatremia (HYP) by VANWART, S, CIRINCIONE, B, LUDWIG, E, CHEN, X, SHOAF, S, GRASELA, T, MALLIKAARJUN, S

Get full text

Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease by Bramer, S L, Forbes, W P, Mallikaarjun, S

“…To study the pharmacokinetics of cilostazol following single oral administration of 50 to 200 mg in healthy young males, and after repeated oral administration…”
Get full text

OI-A-1 by Van Wart, S. A., Cirincione, B. B., Ludwig, E. A., Chen, X., Shoaf, S., Grasela, T. H., Mallikaarjun, S.

“…AIM TOL is a oral vasopressin (V2) receptor antagonist under development for treatment of CHF and/or HYP. Direct and indirect effect PK/PD models were…”
Get full text

PIII-10 by Van Wart, S. A., Cirincione, B. B., Ludwig, E. A., Chen, X., Shoaf, S., Grasela, T. H., Mallikaarjun, S.

“…AIM Direct effect, indirect effect, and competitive antagonism models were evaluated to describe plasma TOL concentration (Cp) effect on urine flow rate (UFR),…”
Get full text

Comparison of Two Doses and Dosing Regimens of Tolvaptan in Congestive Heart Failure by Hauptman, Paul J, Zimmer, Christopher, Udelson, James, Shoaf, Susan E, Mallikaarjun, Suresh, Bramer, Steven L, Orlandi, Cesare

“…Fluid retention and extracellular volume expansion are frequently encountered complications of congestive heart failure (HF) that can cause morbidity and…”
Get full text

P.2.122 Lack of effect of renal and hepatic impairment on the pharmacokinetics of aripiprazole by Bramer, S., Shoaf, S., Salazar, D., Mallikaarjun, S.

Get full text

Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin: The pharmacokinetics of cilostazol by MALLIKAARJUN, S, BRAMER, S. L

Get full text